Department of Periodontology, School of Dental Medicine, Tufts University, Boston, Massachusetts, USA.
Division of Oral Surgery, Unit of Dentistry, Dental School, Faculty of Medicine and Surgery, Vita Salute University and IRCCS San Raffaele, Milan, Italy.
Clin Implant Dent Relat Res. 2022 Dec;24(6):776-791. doi: 10.1111/cid.13126. Epub 2022 Sep 6.
The lateral maxillary sinus augmentation (MSA) procedure has good predictability in terms of the success of bone regeneration with a low incidence of postoperative infections, estimated between 2% and 5.6%. Although the use of antibiotics is an established and standardized prophylactic measure for MSA procedures, the addition of corticosteroids still varies among clinician preference and clinical judgment.
The aim of this systematic review was to identify whether the administration of corticosteroids during the MSA surgical procedure affects postoperative symptoms including swelling, pain, and infection rate.
A literature search through PubMed, EMBASE, Ovid MEDLINE, and Web of Science indices, according to PICO criteria, was conducted to identify whether MSA peri-operative use of corticosteroids reduces the incidence of complications and patient morbidity. A single arm meta-analysis was performed due to the lack of randomized controlled trials (RCTs) comparing groups treated with or without peri-operative corticosteroids. The intracluster correlation co-efficient (ICC) and design effect were calculated to adjust for the clustering design.
In the 37 studies included, a total of 1599 patients (378 Cort, 1221 No-Cort) were analyzed. Before and after taking account of clustering, there was statistically significant effect of corticosteroids on swelling, pain, wound dehiscence, trismus, and hematoma. The complication rates postoperatively were comparable between the two study groups, however slight differences existed in the incidence of active suppuration (1.7% [95% CI 0.7-3.9] Cort vs. 3.2% [2.2-4.5] No-Cort), wound dehiscence (3.9% [1.3-11.2] Cort vs. 2.1% [1.0-4.1] No-Cort) and trismus (2.7% [0.8-8.4] Cort vs. 1.4% [0.8-2.5] No-Cort).
Although the event rate of the 1-to-2-week postoperative complications did not differ between the two groups, the lack of conclusive data and research comparing peri-operative corticosteroid use makes it impossible to draw definitive conclusions and more evidence and studies designed for this specific purpose are needed.
外侧上颌窦提升(MSA)手术在骨再生成功率方面具有良好的预测性,术后感染发生率较低,估计在 2%至 5.6%之间。虽然抗生素的使用是 MSA 手术的一种既定和标准化预防措施,但皮质类固醇的使用仍因临床医生的偏好和临床判断而异。
本系统评价旨在确定 MSA 手术过程中皮质类固醇的给药是否会影响术后肿胀、疼痛和感染率等症状。
根据 PICO 标准,通过 PubMed、EMBASE、Ovid MEDLINE 和 Web of Science 索引进行文献检索,以确定 MSA 围手术期使用皮质类固醇是否会降低并发症和患者发病率的发生率。由于缺乏比较使用或不使用围手术期皮质类固醇的组的随机对照试验(RCT),因此进行了单臂荟萃分析。由于聚类设计,计算了 intracluster 相关系数(ICC)和设计效果以进行调整。
在纳入的 37 项研究中,共分析了 1599 名患者(378 例 Cort,1221 例 No-Cort)。在考虑聚类之前和之后,皮质类固醇对肿胀、疼痛、伤口裂开、牙关紧闭和血肿均有统计学显著影响。两组术后并发症发生率相当,但在化脓性感染(1.7% [95%CI 0.7-3.9] Cort 与 3.2% [2.2-4.5] No-Cort)、伤口裂开(3.9% [1.3-11.2] Cort 与 2.1% [1.0-4.1] No-Cort)和牙关紧闭(2.7% [0.8-8.4] Cort 与 1.4% [0.8-2.5] No-Cort)的发生率方面存在细微差异。
尽管两组在 1 至 2 周术后并发症的发生率没有差异,但由于缺乏比较围手术期皮质类固醇使用的明确数据和研究,因此无法得出明确的结论,需要更多专门为此目的设计的证据和研究。